Register for OBR daily




To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

SNSS $0.65 0.1439 +28.44%
CYTK $11.12 1.1700 +11.76%
SPHS $5.86 0.4600 +8.52%
BDSI $2.55 0.2000 +8.51%
NKTR $17.29 1.1900 +7.39%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

PVCT $0.29 -0.0200 -6.45%
TGTX $5.91 -0.4000 -6.34%
VSTM $1.40 -0.0800 -5.41%
GALE $0.44 -0.0254 -5.40%
NLNK $10.58 -0.5300 -4.77%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | Next > | Last >>

Gary Reedy Readies ACS for Change

(MedPage Today) July 17, 2016 - A "new" American Cancer Society has emerged following a somewhat tortuous 3-year "transformation" process that reorganized the decentralized, century-plus old cancer charity into a more streamlined single-corporate entity, according to ACS CEO Gary Reedy.
read article (free registration required) 



ASCO Chief Medical Officer Featured in Podcast Explaining the TAPUR Study, ASCO’s First Clinical Trial

(ASCO in Action) July 19, 2016 - ASCO Chief Medical Officer Richard L. Schilsky, MD, FASCO, was featured on the Cancer.Net Blog in the July 19 podcast, discussing what the TAPUR Study is and why it is important to patients and the medical community.
read article 



Cerulean Receives FDA Fast Track Designation for CRLX101 for the Treatment of Platinum-Resistant Ovarian Cancer

(StreetInsider) July 19, 2016 - Cerulean Pharma Inc. today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for Cerulean’s lead nanoparticle-drug conjugate, CRLX101, in combination with paclitaxel, for the treatment of platinum-resistant ovarian carcinoma, fallopian tube or primary peritoneal cancer.
read article 



Poor Cancer Care For Native Americans Might Be A Treaty Violation

(Newsweek) July 19, 2016 - Mary Berliner has to travel all over the remote wilderness of southwestern Alaska to care for patients who often need a plane ride to get to a clinic for their specialized care.
read article 



Old Pharma Sees New Profit Cure In Cancer Drugs

(Reuters) July 19, 2016 - Some of the world's largest drug companies are taking out their checkbooks for acquisitions of smaller peers whose cancer drugs have the potential to cure not just patients, but corporate growth prospects as well.
read article 



Why Geographic Cancer Clusters Are Impossible to Prove

(Newsweek) July 18, 2016 - Despite their best efforts, scientists can't prove the connection between industrial plants emitting noxious chemicals and geographical outliers in cancer numbers.
read article 



Tracking Cancer In Real Time

(California Healthline) July 19, 2016 - California is overhauling the way it collects information for its massive cancer database in the hope of improving how patients are treated for the disease.
read article 



Can Big Data Help Cure Cancer?

(InformationWeek) July 19, 2016 - Genomic research and precision medicine are on the leading edge of cancer research and treatment, but the huge size of the data sets and the complexity of sharing those data sets among researchers thwarts progress.
read article 



Genetics Labs Hoarding Cancer Patient Data Could Be Impeding Care

(Newsweek) July 19, 2016 - Cancer data that reveals patterns among family history could speed up innovations and therapies for patients—if the labs that own it will release it.
read article 



Genetic Drivers of Immune Response to Cancer Discovered Through ‘Big Data’ Analysis

(SBP/Beaker blog) July 18, 2016 - Scientists at the Sanford Burnham Prebys Medical Discovery Institute have identified over 100 new genetic regions that affect the immune response to cancer. The findings, published in Cancer Immunology Research, could inform the development of future immunotherapies—treatments that enhance the immune system’s ability to kill tumors.
read article 



Size Matters: Advance Could Increase Sensitivity of Liquid Biopsies

(University of Utah Health Care) July 18, 2016 - A University of Utah School of Medicine-led study reports an advance that could increase the accuracy of liquid biopsies.
read press release 



Some Adolescent Cancer Survivors May Require More Comprehensive Mental Health Screening

(St. Jude Children’s) July 18, 2016 - Research from the Childhood Cancer Survivors Study has identified distinct profiles of psychological symptoms in adolescent cancer survivors; a finding that is expected to advance mental health screening and treatment.
read press release 



I.V.F. Does Not Raise Breast Cancer Risk, Study Shows

(New York Times) July 19, 2016 - The largest study to date shows little evidence of an increased risk in breast cancer among women who have undergone fertility treatments.
read article 



Got Dense Breasts? That Can Depend On Who Is Reading The Mammogram

(NPR/Shots blog) July 18, 2016 - If you're a woman who gets screening mammograms, you may have received a letter telling you that your scan was clear, but that you have dense breasts, a risk factor for breast cancer.
read article 



Metastatic Prostate Cancer Cases Surge, Adding To Screening Controversy

(Philadelphia Inquirer) July 19, 2016 - A new study documents a decade-long increase in the number of men who have incurable prostate cancer at their initial diagnosis, an ominous finding that prostate cancer-screening proponents have been predicting.
read article 



With Celgene Deal, Jounce Lands $261M And a “Trusting Partner”

(Xconomy Boston) July 19, 2016 - It’s getting harder and harder to stand out in the increasingly crowded cancer immunotherapy field. But with a wide-ranging alliance being announced this morning, three-year-old Jounce Therapeutics has been able to make its mark.
read article 



FDA Knocks Back Novartis Copy Of Amgen's Drug Neulasta

(Reuters) July 19, 2016 - U.S. regulators have declined to approve Novartis' so-called biosimilar copy of Amgen's Neulasta drug that fights infections in cancer patients, the Swiss drugmaker said on Tuesday.
read article 



Celgene, Jounce Therapeutics in Early Cancer Immunotherapy Development Pact

(TheStreet) July 19, 2016 - Tuesday's deal has Celgene paying $225 million to privately held Jounce Therapeutics to partner on the development of "next generation" cancer immunotherapies. Celgene is also taking a $36 million equity stake in Jounce.
read article 



ZIOPHARM Provides Update Regarding Phase I Study of Gene Therapy Candidate Ad-RTS-hIL-12 in Brain Cancer

(ZIOPHARM) July 19, 2016 - ZIOPHARM Oncology, Inc. today provided an update regarding the Company's ongoing multicenter Phase I study of Ad-RTS-hIL-12 + orally administered veledimex in recurrent or progressive glioblastoma (GBM) or grade III malignant glioma.
read corporate press release 



Study Finds New Data About dMMR's Hereditary Basis In Rectal Cancer

(MD Anderson) July 18, 2016 - Up to 15 percent of colorectal cancers show a genetic mutation known as DNA mismatch repair deficiency, or dMMR. Until now, little has been known about how the mutation behaves in rectal cancer patients, what causes dMMR, and which treatments may be most effective.
read press release 



Fraud Concerns Emerge As Compounding Drug Sales Skyrocket

(Kaiser Health News) July 18, 2016 - Government spending on “compounded” drugs that are handmade by retail pharmacists has skyrocketed, drawing the attention of federal investigators who are raising fraud and overbilling concerns.
read article 



BIO Statement on Prescription Drug User Fee Act Goals Letter

(BIO.org) July 15, 2016 - Biotechnology Innovation Organization (BIO) President and CEO Jim Greenwood released the following statement today regarding the Prescription Drug User Fee Act (PDUFA) VI goals letter:
read press release 



The Next PDUFA: New Performance and Procedural Goals

(Regulatory Focus) July 15, 2016 - Exactly one year after the first round of negotiations over the sixth iteration of the Prescription Drug User Fee Act (PDUFA), the US Food and Drug Administration (FDA) on Friday released the full details of the performance and procedural goals for fiscal years 2018 through 2022.
read article 



Makers of Humira and Enbrel Using New Drug Patents to Delay Generic Versions

(New York Times) July 15, 2016 - The best-selling drugs Humira and Enbrel have a lot in common. They both use biotechnology to treat rheumatoid arthritis, psoriasis and other autoimmune diseases. And they come with giant price tags approaching $50,000 a year.
read article 



5 Health And Medicine Issues To Watch For At The GOP Convention

(STAT) July 18, 2016 - Until now, health care hasn’t been a big part of Donald Trump’s campaign for the presidency. But conventions are about more than the nominee, and Republicans are likely to have something to say about issues including Obamacare, abortion, and perhaps even medical research.
read article